All In Biotech

Drug Trial Radar · NCT05819775

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age

Last checked: Nov 20, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

22

Actual

Start

May 30, 2023

Primary completion

Nov 19, 2025

Study completion Nov 19, 2025

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Apr 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the safety, PK / PD, and efficacy of SC CSL312 for prophylactic treatment of pediatric subjects with HAE.

Conditions

  • Hereditary Angioedema (HAE)

Interventions

  • CSL312Biological

    Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously (SC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAE)Time frame: Up to Month 12
  2. Percentage of Participants With TEAETime frame: Up to Month 12
  3. Number of TEAETime frame: Up to Month 12
  4. TEAE Rates Per InjectionTime frame: Up to Month 12
  5. TEAE Rates Per Participant-YearTime frame: Up to Month 12
  6. Maximum Concentration (Cmax) of CSL312 at Steady-stateTime frame: Up to Month 12
  7. Trough Concentration (Ctrough) of CSL312 at Steady-stateTime frame: At Months 3, 4, 6, 9, 10, and 12
  8. Time to Maximum Concentration (Tmax) of CSL312 at Steady-StateTime frame: Up to Month 12

Locations

13 sites in 5 countries. Site status is shown where the registry gives one.

  • Research Solutions of Arizona

    Litchfield Park, Arizona

  • Medical Research of Arizona

    Scottsdale, Arizona

  • Donald S. Levy M.D.

    Orange, California

  • Raffi Tachdjian MD, Inc.

    Santa Monica, California

  • Bernstein Clinical Research

    Cincinnati, Ohio

  • PennState Health Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • AARA Research Center

    Dallas, Texas

  • Campbelltown Hospital, Western Sydney University

    Campbelltown, Australia

  • Ottawa Allergy Research Corp

    Ottawa, Canada

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt am Main, Germany

  • HZRM Hämophilie Zentrum Rhein Main GmbH

    Frankfurt am Main, Hesse, Germany

  • Barzilai University Medical Center

    Ashkelon, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.